Published in Int Immunol on September 11, 2006
HMGB1: endogenous danger signaling. Mol Med (2008) 4.02
Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes (2008) 1.17
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
HMGB1, an innate alarmin, in the pathogenesis of type 1 diabetes. Int J Clin Exp Pathol (2009) 1.00
Armed response: how dying cells influence T-cell functions. Immunol Rev (2011) 0.99
HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen. Vaccine (2010) 0.92
Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine (2010) 0.91
Retracted Increased serum high mobility group box-1 level in Churg-Strauss syndrome. Clin Exp Immunol (2007) 0.89
HMGB1 and cord blood: its role as immuno-adjuvant factor in innate immunity. PLoS One (2011) 0.88
Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J Immunol (2013) 0.86
TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant. J Transl Med (2014) 0.84
Surfactant protein-A inhibits mycoplasma-induced dendritic cell maturation through regulation of HMGB-1 cytokine activity. J Immunol (2010) 0.80
High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines. Immunology (2014) 0.79
Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes. BMC Immunol (2013) 0.78
High-mobility-group box chromosomal protein 1 as a new target for modulating stress response. Surg Today (2010) 0.77
Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control. Int J Radiat Oncol Biol Phys (2017) 0.76
Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles. Breast Cancer Res (2015) 0.76
The western-type diet induces anti-HMGB1 autoimmunity in Apoe(-/-) mice. Atherosclerosis (2016) 0.75
Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization. Mol Immunol (2013) 0.75
HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape. Oncotarget (2017) 0.75
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature (2002) 12.09
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57
Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A (2003) 7.14
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med (2004) 6.38
HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol (2011) 6.23
Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science (2011) 5.87
Sepsis definitions: time for change. Lancet (2013) 5.63
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest (2005) 3.99
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet (2013) 3.83
A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A (2010) 3.80
Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med (2003) 3.75
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A (2002) 3.68
Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med (2006) 3.66
Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med (2007) 3.63
Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med (2005) 3.58
Theoretical, empirical and practical approaches to resolving the unmet information needs of clinical information system users. Proc AMIA Symp (2002) 3.45
Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med (2007) 3.27
Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med (2006) 3.26
Effectiveness of first eight methadone maintenance treatment clinics in China. AIDS (2007) 3.18
Novel role of PKR in inflammasome activation and HMGB1 release. Nature (2012) 3.13
The cytokine activity of HMGB1. J Leukoc Biol (2005) 3.02
Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med (2005) 3.01
HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology (2002) 2.95
The "cytokine profile": a code for sepsis. Trends Mol Med (2005) 2.89
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 2.89
Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol (2010) 2.88
Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med (2002) 2.83
Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med (2012) 2.79
Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med (2004) 2.79
Induction of pluripotency in mouse somatic cells with lineage specifiers. Cell (2013) 2.69
Scaling up the national methadone maintenance treatment program in China: achievements and challenges. Int J Epidemiol (2010) 2.65
Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A (2008) 2.58
Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol (2003) 2.50
Use of online resources while using a clinical information system. AMIA Annu Symp Proc (2003) 2.49
The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology (2006) 2.47
High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol (2006) 2.44
Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med (2007) 2.41
Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest (2005) 2.40
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood (2011) 2.37
Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood (2008) 2.35
Network of dynamic interactions between histone H1 and high-mobility-group proteins in chromatin. Mol Cell Biol (2004) 2.33
High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol (2004) 2.32
Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med (2003) 2.30
Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med (2006) 2.27
High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev (2006) 2.26
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages. Anesthesiology (2014) 2.24
IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol (2003) 2.24
The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol (2013) 2.22
Alarmins: awaiting a clinical response. J Clin Invest (2012) 2.19
Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods (2004) 2.14
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood (2012) 2.14
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14
The cholinergic anti-inflammatory pathway. Brain Behav Immun (2005) 2.13
Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol (2011) 2.11
Targeting HMGB1 in inflammation. Biochim Biophys Acta (2009) 2.11
ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem (2005) 2.11
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood (2011) 2.09
Analysis of polarity information in medical text. AMIA Annu Symp Proc (2005) 2.07
HMGB1 as a DNA-binding cytokine. J Leukoc Biol (2002) 2.07